These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 22987022)

  • 21. Atomoxetine and osmotically released methylphenidate for the treatment of attention deficit hyperactivity disorder: acute comparison and differential response.
    Newcorn JH; Kratochvil CJ; Allen AJ; Casat CD; Ruff DD; Moore RJ; Michelson D;
    Am J Psychiatry; 2008 Jun; 165(6):721-30. PubMed ID: 18281409
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Atomoxetine treatment of attention-deficit/hyperactivity disorder in young adults with assessment of functional outcomes: a randomized, double-blind, placebo-controlled clinical trial.
    Durell TM; Adler LA; Williams DW; Deldar A; McGough JJ; Glaser PE; Rubin RL; Pigott TA; Sarkis EH; Fox BK
    J Clin Psychopharmacol; 2013 Feb; 33(1):45-54. PubMed ID: 23277268
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Randomized clinical study of a histamine H3 receptor antagonist for the treatment of adults with attention-deficit hyperactivity disorder.
    Weisler RH; Pandina GJ; Daly EJ; Cooper K; Gassmann-Mayer C;
    CNS Drugs; 2012 May; 26(5):421-34. PubMed ID: 22519922
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Open-label atomoxetine for attention-deficit/ hyperactivity disorder symptoms associated with high-functioning pervasive developmental disorders.
    Posey DJ; Wiegand RE; Wilkerson J; Maynard M; Stigler KA; McDougle CJ
    J Child Adolesc Psychopharmacol; 2006 Oct; 16(5):599-610. PubMed ID: 17069548
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Safety and tolerability of atomoxetine over 3 to 4 years in children and adolescents with ADHD.
    Donnelly C; Bangs M; Trzepacz P; Jin L; Zhang S; Witte MM; Ball SG; Spencer TJ
    J Am Acad Child Adolesc Psychiatry; 2009 Feb; 48(2):176-85. PubMed ID: 20040824
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A randomized double-blind trial of atomoxetine for cognitive impairments in 32 people with schizophrenia.
    Kelly DL; Buchanan RW; Boggs DL; McMahon RP; Dickinson D; Nelson M; Gold JM; Ball MP; Feldman S; Liu F; Conley RR
    J Clin Psychiatry; 2009 Apr; 70(4):518-25. PubMed ID: 19358788
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Atomoxetine: a new treatment for Attention Deficit/Hyperactivity Disorder (ADHD) in children and adolescents].
    Purper-Ouakil D; Fourneret P; Wohl M; Rénéric JP
    Encephale; 2005; 31(3):337-48. PubMed ID: 16142049
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Once-daily atomoxetine treatment for children with attention-deficit/hyperactivity disorder, including an assessment of evening and morning behavior: a double-blind, placebo-controlled trial.
    Kelsey DK; Sumner CR; Casat CD; Coury DL; Quintana H; Saylor KE; Sutton VK; Gonzales J; Malcolm SK; Schuh KJ; Allen AJ
    Pediatrics; 2004 Jul; 114(1):e1-8. PubMed ID: 15231966
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Atomoxetine: the first nonstimulant for the management of attention-deficit/hyperactivity disorder.
    Corman SL; Fedutes BA; Culley CM
    Am J Health Syst Pharm; 2004 Nov; 61(22):2391-9. PubMed ID: 15581262
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dose-dependent Raynaud's phenomenon developing from use of atomoxetine in a girl.
    Gökçen C; Kutuk MO; Coşkun Ş
    J Child Adolesc Psychopharmacol; 2013 Aug; 23(6):428-30. PubMed ID: 23952193
    [No Abstract]   [Full Text] [Related]  

  • 31. Placebo-controlled trial of atomoxetine for weight reduction in people with schizophrenia treated with clozapine or olanzapine.
    Ball MP; Warren KR; Feldman S; McMahon RP; Kelly DL; Buchanan RW
    Clin Schizophr Relat Psychoses; 2011 Apr; 5(1):17-25. PubMed ID: 21459735
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The efficacy of atomoxetine for the treatment of children and adolescents with attention-deficit/hyperactivity disorder: a comprehensive review of over a decade of clinical research.
    Savill NC; Buitelaar JK; Anand E; Day KA; Treuer T; Upadhyaya HP; Coghill D
    CNS Drugs; 2015 Feb; 29(2):131-51. PubMed ID: 25698145
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term safety and tolerability of atomoxetine in Japanese adults with attention deficit hyperactivity disorder.
    Hirata Y; Goto T; Takita Y; Trzepacz PT; Allen AJ; Ichikawa H; Takahashi M
    Asia Pac Psychiatry; 2014 Sep; 6(3):292-301. PubMed ID: 24376099
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A placebo-controlled trial of atomoxetine in marijuana-dependent individuals with attention deficit hyperactivity disorder.
    McRae-Clark AL; Carter RE; Killeen TK; Carpenter MJ; White KG; Brady KT
    Am J Addict; 2010; 19(6):481-9. PubMed ID: 20958842
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Relationships Between Functional Outcomes and Symptomatic Improvement in Atomoxetine-Treated Adult Patients with Attention-Deficit/Hyperactivity Disorder: Post Hoc Analysis of an Integrated Database.
    De Bruyckere K; Bushe C; Bartel C; Berggren L; Kan CC; Dittmann RW
    CNS Drugs; 2016 Jun; 30(6):541-58. PubMed ID: 27224994
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of two different methods of initiating atomoxetine on the adverse event profile of atomoxetine.
    Greenhill LL; Newcorn JH; Gao H; Feldman PD
    J Am Acad Child Adolesc Psychiatry; 2007 May; 46(5):566-572. PubMed ID: 17450047
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Atomoxetine in children with attention-deficit hyperactivity disorder with prior stimulant therapy: a prospective open-label study.
    Hammerness P; Doyle R; Kotarski M; Georgiopoulos A; Joshi G; Zeitlin S; Biederman J
    Eur Child Adolesc Psychiatry; 2009 Aug; 18(8):493-8. PubMed ID: 19377865
    [TBL] [Abstract][Full Text] [Related]  

  • 38. High-dose atomoxetine treatment of ADHD in youths with limited response to standard doses.
    Kratochvil CJ; Michelson D; Newcorn JH; Weiss MD; Busner J; Moore RJ; Ruff DD; Ramsey J; Dickson R; Turgay A; Saylor KE; Luber S; Vaughan B; Allen AJ;
    J Am Acad Child Adolesc Psychiatry; 2007 Sep; 46(9):1128-1137. PubMed ID: 17712236
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Spotlight on atomoxetine in adults with attention-deficit hyperactivity disorder.
    Simpson D; Plosker GL
    CNS Drugs; 2004; 18(6):397-401. PubMed ID: 15089111
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A randomized double-blind study of atomoxetine versus placebo for attention-deficit/hyperactivity disorder symptoms in children with autism spectrum disorder.
    Harfterkamp M; van de Loo-Neus G; Minderaa RB; van der Gaag RJ; Escobar R; Schacht A; Pamulapati S; Buitelaar JK; Hoekstra PJ
    J Am Acad Child Adolesc Psychiatry; 2012 Jul; 51(7):733-41. PubMed ID: 22721596
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.